Merit Medical Systems, Inc.
This article was originally published in The Gray Sheet
Begins integrating Mallinckrodt catheter unit following completion of the acquisition, announced Aug. 25 (1"The Gray Sheet" July 26, p. 24)
You may also be interested in...
Merit Medical Systems will acquire Mallinckrodt's $10 mil.-per-year diagnostic and interventional catheter production facility in Angleton, Texas for undisclosed terms under a July 21 agreement in principle. The purchase "strengthens our sales and new product development objectives by adding...revenue as well as providing a depth of core technology for future catheter development," Merit Chairman and CEO Fred Lampropoulos explains. Strategically, the non-core Mallinckrodt business complements Merit's current offerings and will allow consolidation of some existing catheter products into the Angleton facility for greater plant utilization. The deal is expected to close in August subject to a binding agreement. Separately, Merit announces a 28% increase in second-quarter net income to $752,684 on revenues of $19 mil., up 5.6%
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.